NASDAQ:VSAR - Versartis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.50 -0.05 (-3.23 %)
(As of 05/22/2018 07:34 AM ET)
Previous Close$1.55
Today's Range$1.50 - $1.55
52-Week Range$1.35 - $22.10
Volume161,875 shs
Average Volume364,530 shs
Market Capitalization$55.93 million
P/E Ratio-0.62
Dividend YieldN/A
Beta2.1

About Versartis (NASDAQ:VSAR)

Versartis logoVersartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VSAR
CUSIPN/A
Phone650-963-8580

Debt

Debt-to-Equity Ratio0.09
Current Ratio21.29
Quick Ratio21.29

Price-To-Earnings

Trailing P/E Ratio-0.62
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales1,353.00
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book0.65

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-84,970,000.00
Net MarginsN/A
Return on Equity-84.63%
Return on Assets-53.05%

Miscellaneous

Employees28
Outstanding Shares36,080,000

Versartis (NASDAQ:VSAR) Frequently Asked Questions

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis (NASDAQ:VSAR) posted its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.86) by $0.61. View Versartis' Earnings History.

When is Versartis' next earnings date?

Versartis is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Versartis.

What price target have analysts set for VSAR?

9 brokerages have issued 1 year price targets for Versartis' stock. Their predictions range from $3.00 to $14.00. On average, they expect Versartis' stock price to reach $5.1250 in the next year. View Analyst Ratings for Versartis.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:
  • Mr. Jay P. Shepard, CEO, Pres, Principal Financial Officer & Director (Age 60)
  • Dr. Jeffrey L. Cleland, Co-Founder and Sr. Scientific Advisor to the Chief Exec. Officer (Age 53)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Kevin Haas, VP of Fin. & Principal Accounting Officer (Age 53)
  • Mr. Shane M. Ward, Sr. VP & Gen. Counsel (Age 43)

Has Versartis been receiving favorable news coverage?

Media coverage about VSAR stock has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Versartis earned a daily sentiment score of 0.20 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.55 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Versartis' major shareholders?

Versartis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Guggenheim Capital LLC (2.31%), Dimensional Fund Advisors LP (1.71%), GSA Capital Partners LLP (0.44%), JPMorgan Chase & Co. (0.39%), Schwab Charles Investment Management Inc. (0.36%) and A.R.T. Advisors LLC (0.25%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay S Stout, Jay Shepard, John Varian, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Perceptive Advisors Llc, Shahzad Malik, Shane Ward, Srinivas Akkaraju and Tracy M Woody. View Institutional Ownership Trends for Versartis.

Which major investors are selling Versartis stock?

VSAR stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and Guggenheim Capital LLC. Company insiders that have sold Versartis company stock in the last year include Colin Hislop, Jay S Stout, Jay Shepard, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Shane Ward and Tracy M Woody. View Insider Buying and Selling for Versartis.

Which major investors are buying Versartis stock?

VSAR stock was bought by a variety of institutional investors in the last quarter, including A.R.T. Advisors LLC, Schwab Charles Investment Management Inc., California Public Employees Retirement System, Dimensional Fund Advisors LP and GSA Capital Partners LLP. Company insiders that have bought Versartis stock in the last two years include Perceptive Advisors Llc and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy shares of Versartis?

Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of VSAR stock can currently be purchased for approximately $1.50.

How big of a company is Versartis?

Versartis has a market capitalization of $55.93 million and generates $40,000.00 in revenue each year. The biopharmaceutical company earns $-84,970,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Versartis employs 28 workers across the globe.

How can I contact Versartis?

Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected]


MarketBeat Community Rating for Versartis (VSAR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Versartis (NASDAQ:VSAR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Versartis in the last 12 months. Their average twelve-month price target is $5.1250, suggesting that the stock has a possible upside of 241.67%. The high price target for VSAR is $14.00 and the low price target for VSAR is $3.00. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.112.112.222.30
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.1250$5.1250$5.6250$7.2222
Price Target Upside: 241.67% upside230.65% upside196.05% upside280.12% upside

Versartis (NASDAQ:VSAR) Consensus Price Target History

Price Target History for Versartis (NASDAQ:VSAR)

Versartis (NASDAQ:VSAR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2018Canaccord GenuityDowngradeBuy ➝ Hold$9.00 ➝ $5.00HighView Rating Details
10/27/2017Cantor FitzgeraldSet Price TargetBuy$14.00N/AView Rating Details
9/25/2017Bank of AmericaDowngradeBuy ➝ NeutralHighView Rating Details
9/25/2017CitigroupDowngradeBuy ➝ Neutral$23.00 ➝ $3.00HighView Rating Details
9/22/2017Morgan StanleyReiterated RatingEqual Weight$3.00 ➝ $4.00N/AView Rating Details
9/22/2017SunTrust BanksDowngradeBuy ➝ Hold$25.00 ➝ $4.00N/AView Rating Details
9/22/2017CowenDowngradeOutperform ➝ Market Perform$45.00 ➝ $3.00N/AView Rating Details
9/22/2017BarclaysDowngradeOverweight ➝ Equal Weight$28.00 ➝ $4.00N/AView Rating Details
9/22/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$26.00 ➝ $4.00N/AView Rating Details
12/20/2016Credit Suisse GroupUpgradeNeutral ➝ Outperform$11.00 ➝ $20.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Versartis (NASDAQ:VSAR) Earnings History and Estimates Chart

Earnings by Quarter for Versartis (NASDAQ:VSAR)

Versartis (NASDAQ:VSAR) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.15 EPS

Versartis (NASDAQ VSAR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018($0.96)N/AView Earnings Details
5/8/2018Q1 2018($0.86)($0.25)ViewN/AView Earnings Details
3/1/2018Q4 2017($0.9070)$0.8670$0.04 millionViewN/AView Earnings Details
10/26/2017Q3 2017($0.62)($1.40)ViewN/AView Earnings Details
7/27/2017Q2 2017($0.84)($1.0360)ViewN/AView Earnings Details
4/27/2017Q1 2017($0.71)($0.85)ViewN/AView Earnings Details
2/21/2017Q4 2016($0.62)($0.64)$10.00 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.81)($0.92)ViewN/AView Earnings Details
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
4/28/2016Q1 2016($0.72)($0.82)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
8/5/2014Q2 2014($0.36)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Versartis (NASDAQ:VSAR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Versartis (NASDAQ VSAR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 37.41%
Insider Trading History for Versartis (NASDAQ:VSAR)
Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Versartis (NASDAQ VSAR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/24/2018Jay S StoutSVPSell4,854$1.55$7,523.70185,646View SEC Filing  
3/23/2018Tracy M WoodyInsiderSell4,345$1.75$7,603.75215,755View SEC Filing  
2/8/2018Jay ShepardInsiderSell14,446$1.80$26,002.80602,298View SEC Filing  
2/8/2018Kevin HaasVPSell1,599$1.80$2,878.2078,218View SEC Filing  
2/8/2018Paul WestbergSVPSell5,355$1.80$9,639.00225,736View SEC Filing  
12/4/2017Srinivas AkkarajuDirectorBuy513,872$2.21$1,135,657.1214,955View SEC Filing  
12/1/2017Srinivas AkkarajuDirectorBuy419,700$2.13$893,961.0014,955View SEC Filing  
10/19/2017Colin HislopInsiderSell667$2.55$1,700.8523,833View SEC Filing  
10/19/2017Joshua T BrummCFOSell1,326$2.55$3,381.30201,269View SEC Filing  
10/19/2017Shane WardSVPSell776$2.55$1,978.8092,574View SEC Filing  
9/22/2017Life Sciences Maste PerceptiveMajor ShareholderSell2,130,000$3.29$7,007,700.00View SEC Filing  
6/13/2017Joshua T BrummCFOSell1,421$16.05$22,807.05105,595View SEC Filing  
6/13/2017Paul WestbergSVPSell711$16.05$11,411.5567,517View SEC Filing  
5/16/2017Joshua T. BrummCFOSell1,263$17.40$21,976.20View SEC Filing  
4/19/2017Paul WestbergSVPSell1,316$19.85$26,122.6068,228View SEC Filing  
4/4/2017Colin HislopInsiderSell35,000$21.20$742,000.0059,500View SEC Filing  
3/24/2017Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.2511,475View SEC Filing  
3/17/2017Shahzad MalikDirectorSell483,670$18.11$8,759,263.709,200View SEC Filing  
3/15/2017Shahzad MalikDirectorSell166,330$19.09$3,175,239.709,200View SEC Filing  
3/15/2017Shane WardSVPSell2,041$19.01$38,799.4137,126View SEC Filing  
2/27/2017Jay ShepardInsiderSell5,166$24.00$123,984.00219,024View SEC Filing  
2/27/2017Paul WestbergSVPSell12,500$22.50$281,250.0077,053View SEC Filing  
2/23/2017Jay ShepardInsiderSell16,000$19.25$308,000.00221,858View SEC Filing  
2/23/2017Paul WestbergSVPSell25,000$18.75$468,750.0087,954View SEC Filing  
2/13/2017Perceptive Advisors LlcMajor ShareholderBuy94,016$15.30$1,438,444.80View SEC Filing  
2/9/2017Perceptive Advisors LlcMajor ShareholderBuy145,823$13.72$2,000,691.56View SEC Filing  
2/3/2017Jay ShepardInsiderSell6,719$13.69$91,983.11213,858View SEC Filing  
2/2/2017Jay ShepardInsiderSell24,211$13.77$333,385.47234,046View SEC Filing  
1/30/2017Jay ShepardInsiderSell17,270$13.52$233,490.40220,058View SEC Filing  
1/30/2017Joshua T BrummCFOSell2,945$13.85$40,788.25108,724View SEC Filing  
1/30/2017Paul WestbergSVPSell1,916$13.85$26,536.6071,460View SEC Filing  
1/11/2017Paul WestbergVPSell7,931$15.24$120,868.4446,912View SEC Filing  
1/10/2017Paul WestbergVPSell11,213$15.66$175,595.5846,912View SEC Filing  
1/9/2017Paul WestbergVPSell13,356$15.93$212,761.0846,912View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$14.66$1,389,035.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy47,375$14.37$680,778.75View SEC Filing  
12/27/2016Joshua T BrummCFOSell990$15.85$15,691.5064,824View SEC Filing  
12/27/2016Paul WestbergVPSell361$15.85$5,721.8544,600View SEC Filing  
12/16/2016Paul WestbergVPSell5,000$15.00$75,000.0049,961View SEC Filing  
12/8/2016Edmon R JenningsDirectorSell1,500$12.96$19,440.007,700View SEC Filing  
12/7/2016Joshua T BrummCFOSell3,021$13.25$40,028.2565,814View SEC Filing  
10/3/2016Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.2511,475View SEC Filing  
8/25/2016John VarianDirectorSell1,600$12.97$20,752.007,600View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96155,358View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.2458,835View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.7534,961View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.5560,283View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.4035,686View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.6035,548View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.2820,216View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.0036,538View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.0025,075View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Versartis (NASDAQ VSAR) News Headlines

Source:
DateHeadline
Versartis (VSAR) Receives Average Recommendation of "Hold" from BrokeragesVersartis (VSAR) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 13 at 5:55 AM
Versartis (VSAR) Posts  Earnings Results, Beats Estimates By $0.61 EPSVersartis (VSAR) Posts Earnings Results, Beats Estimates By $0.61 EPS
www.americanbankingnews.com - May 9 at 1:43 PM
BRIEF-Versartis Q1 Loss Per Share $0.25BRIEF-Versartis Q1 Loss Per Share $0.25
www.reuters.com - May 9 at 8:20 AM
BRIEF-Versartis Says Board Approved Plan Of Termination To Eliminate A Number Of Positions Effective Oct 20, 2017BRIEF-Versartis Says Board Approved Plan Of Termination To Eliminate A Number Of Positions Effective Oct 20, 2017
www.reuters.com - May 9 at 8:20 AM
Versartis: 1Q Earnings SnapshotVersartis: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:20 AM
Versartis Reports First Quarter 2018 Financial ResultsVersartis Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 5:38 PM
Versartis (VSAR) Set to Announce Quarterly Earnings on MondayVersartis (VSAR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 2 at 8:15 PM
Versartis (VSAR) Upgraded by ValuEngine to HoldVersartis (VSAR) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 2 at 2:02 PM
Versartis (VSAR) Given a $26.00 Price Target by Piper Jaffray AnalystsVersartis (VSAR) Given a $26.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 20 at 2:25 PM
Detailed Research: Economic Perspectives on PacWest, HD Supply, Limelight Networks, Clean Harbors, Versartis, and ...Detailed Research: Economic Perspectives on PacWest, HD Supply, Limelight Networks, Clean Harbors, Versartis, and ...
globenewswire.com - April 20 at 8:25 AM
Versartis (VSAR) Receives Consensus Recommendation of "Hold" from BrokeragesVersartis (VSAR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 5:45 AM
Versartis (VSAR) Scheduled to Post Quarterly Earnings on WednesdayVersartis (VSAR) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 4:38 AM
Zacks Investment Research Downgrades Versartis (VSAR) to SellZacks Investment Research Downgrades Versartis (VSAR) to Sell
www.americanbankingnews.com - April 14 at 10:43 AM
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Solid Biosciences, Medicines Co., Versartis, and ...Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Solid Biosciences, Medicines Co., Versartis, and ...
www.prnewswire.com - April 11 at 8:32 AM
Versartis (VSAR) Rating Lowered to Neutral at CitigroupVersartis (VSAR) Rating Lowered to Neutral at Citigroup
www.americanbankingnews.com - April 8 at 8:05 PM
Versartis (VSAR) Stock Rating Upgraded by ValuEngineVersartis (VSAR) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 2 at 10:52 PM
Versartis (VSAR) Given Average Recommendation of "Hold" by BrokeragesVersartis (VSAR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 7:02 AM
Versartis Inc (VSAR) Files 10-K for the Fiscal Year Ended on December 31, 2017Versartis Inc (VSAR) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 7 at 8:20 AM
Ascend Capital LLC Acquires 97,184 Shares of Versartis Inc (VSAR)Ascend Capital LLC Acquires 97,184 Shares of Versartis Inc (VSAR)
www.americanbankingnews.com - March 3 at 4:25 AM
Versartis (VSAR) Stock Rating Lowered by Canaccord GenuityVersartis (VSAR) Stock Rating Lowered by Canaccord Genuity
www.americanbankingnews.com - March 2 at 11:24 PM
After-Hours Stock Movers 03/01: (DRRX) (VSAR) (GPS) Higher; (OPK) (AOBC) (OMER) Lower (more...)After-Hours Stock Movers 03/01: (DRRX) (VSAR) (GPS) Higher; (OPK) (AOBC) (OMER) Lower (more...)
www.streetinsider.com - March 2 at 6:09 PM
Versartis (VSAR) Issues Quarterly  Earnings ResultsVersartis (VSAR) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 2 at 12:44 PM
Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 2 at 8:17 AM
Versartis posts 4Q profitVersartis posts 4Q profit
finance.yahoo.com - March 2 at 8:17 AM
Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateVersartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 1 at 5:51 PM
Versartis Inc (VSAR) Given Consensus Rating of "Hold" by AnalystsVersartis Inc (VSAR) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 27 at 5:28 AM
Versartis (VSAR) Set to Announce Quarterly Earnings on WednesdayVersartis (VSAR) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:40 AM
Insider Selling: Versartis Inc (VSAR) Insider Sells 14,446 Shares of StockInsider Selling: Versartis Inc (VSAR) Insider Sells 14,446 Shares of Stock
www.americanbankingnews.com - February 12 at 7:08 PM
BRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis IncBRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc
www.reuters.com - February 8 at 8:12 AM
Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?
finance.yahoo.com - February 5 at 9:40 AM
Zacks: Analysts Expect Versartis, Inc. (VSAR) Will Post Earnings of -$1.05 Per ShareZacks: Analysts Expect Versartis, Inc. (VSAR) Will Post Earnings of -$1.05 Per Share
www.americanbankingnews.com - January 16 at 7:56 PM
Versartis, Inc. (VSAR) Receives Average Recommendation of "Hold" from AnalystsVersartis, Inc. (VSAR) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 8 at 3:54 AM
Exelixis (EXEL) & Versartis (VSAR) Financial AnalysisExelixis (EXEL) & Versartis (VSAR) Financial Analysis
www.americanbankingnews.com - December 25 at 3:24 PM
Versartis, Inc. (VSAR) Given Average Recommendation of "Hold" by AnalystsVersartis, Inc. (VSAR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 14 at 3:30 AM
-$0.98 EPS Expected for Versartis, Inc. (VSAR) This Quarter-$0.98 EPS Expected for Versartis, Inc. (VSAR) This Quarter
www.americanbankingnews.com - December 13 at 9:16 PM
Srinivas Akkaraju Buys 419,700 Shares of Versartis, Inc. (VSAR) StockSrinivas Akkaraju Buys 419,700 Shares of Versartis, Inc. (VSAR) Stock
www.americanbankingnews.com - December 5 at 8:58 PM
Insider Buying: Versartis, Inc. (VSAR) Director Buys 513,872 Shares of StockInsider Buying: Versartis, Inc. (VSAR) Director Buys 513,872 Shares of Stock
www.americanbankingnews.com - December 5 at 8:34 PM
Analyzing pSivida (PSDV) and Versartis (VSAR)Analyzing pSivida (PSDV) and Versartis (VSAR)
www.americanbankingnews.com - December 1 at 5:40 AM
 Brokerages Expect Versartis, Inc. (VSAR) Will Announce Earnings of -$0.98 Per Share Brokerages Expect Versartis, Inc. (VSAR) Will Announce Earnings of -$0.98 Per Share
www.americanbankingnews.com - November 25 at 11:26 PM
Versartis, Inc. (VSAR) Receives Average Rating of "Hold" from AnalystsVersartis, Inc. (VSAR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 19 at 6:16 AM
Versartis, Inc. (VSAR) Expected to Announce Earnings of -$0.98 Per ShareVersartis, Inc. (VSAR) Expected to Announce Earnings of -$0.98 Per Share
www.americanbankingnews.com - November 7 at 5:32 AM
Cantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price TargetCantor Fitzgerald Analysts Give Versartis, Inc. (VSAR) a $14.00 Price Target
www.americanbankingnews.com - October 28 at 11:10 AM
Versartis (VSAR) Taps Cowen to Assist in Evaluating Potential Strategic TransactionsVersartis (VSAR) Taps Cowen to Assist in Evaluating Potential Strategic Transactions
www.streetinsider.com - October 28 at 8:25 AM
Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateVersartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - October 28 at 8:25 AM
Versartis Hires Cowen to Assist in Evaluating Potential Strategic TransactionsVersartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions
finance.yahoo.com - October 28 at 8:25 AM
Versartis, Inc. (VSAR) Posts Quarterly  Earnings Results, Misses Expectations By $0.78 EPSVersartis, Inc. (VSAR) Posts Quarterly Earnings Results, Misses Expectations By $0.78 EPS
www.americanbankingnews.com - October 27 at 3:40 PM
Head to Head Review: Versartis (VSAR) versus AcelRx Pharmaceuticals (ACRX)Head to Head Review: Versartis (VSAR) versus AcelRx Pharmaceuticals (ACRX)
www.americanbankingnews.com - October 27 at 3:06 AM
Versartis, Inc. (VSAR) Given Average Rating of "Hold" by AnalystsVersartis, Inc. (VSAR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 25 at 7:34 AM
Versartis, Inc. (VSAR) Set to Announce Quarterly Earnings on WednesdayVersartis, Inc. (VSAR) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Zacks: Analysts Anticipate Versartis, Inc. (VSAR) to Announce -$0.68 Earnings Per ShareZacks: Analysts Anticipate Versartis, Inc. (VSAR) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - October 18 at 12:28 PM

SEC Filings

Versartis (NASDAQ:VSAR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Versartis (NASDAQ:VSAR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Versartis (NASDAQ VSAR) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.